| CLNNW Stock | | | USD 0.03 0.01 21.55% |
Executive
Mary Mcneil is Head Resources of Clene Inc
| Address | 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121 |
| Phone | 801 676 9695 |
| Web | https://clene.com |
Clene Management Efficiency
The company has return on total asset
(ROA) of
(0.4171) % which means that it has lost $0.4171 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(2.8966) %, meaning that it generated substantial loss on money invested by shareholders. Clene's management efficiency ratios could be used to measure how well Clene manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.99 in 2024.
Return On Capital Employed is likely to drop to -1.58 in 2024. At this time, Clene's
Non Currrent Assets Other are fairly stable compared to the past year.
Net Tangible Assets is likely to climb to about 5.9
M in 2024, whereas
Other Current Assets are likely to drop slightly above 2.2
M in 2024.
Clene Inc has accumulated 32.16
M in total debt with debt to equity ratio
(D/E) of 0.11, which may suggest the company is not taking enough advantage from borrowing. Clene Inc has a current ratio of 6.78, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Note, when we think about Clene's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The companys products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc is traded on NASDAQ Exchange in the United States. Clene Inc (CLNNW) is traded on NASDAQ Exchange in USA. It is located in 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121 and employs 82 people. Clene is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Clene Inc Leadership Team
Elected by the shareholders, the Clene's board of directors comprises two types of representatives: Clene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clene. The board's role is to monitor Clene's management team and ensure that shareholders' interests are well served. Clene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Chief Officer | |
| Jeong Ted, Chief Officer | |
| Mark ESQ, Chief Officer | |
| Michael Hotchkin, Chief Officer | |
| Robert MBA, President CEO | |
| Rob Etherington, Pres CEO | |
| Mark Mortenson, CoFounder Officer | |
| Mary Mcneil, Head Resources | |
| MHS MD, Head Medical | |
| Jerry JD, General Secretary | |
Clene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Clene Stock Analysis
When running Clene's price analysis, check to
measure Clene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clene is operating at the current time. Most of Clene's value examination focuses on studying past and present price action to
predict the probability of Clene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clene's price. Additionally, you may evaluate how the addition of Clene to your portfolios can decrease your overall portfolio volatility.